SAB Biotherapeutics has raised $22 million in its Series A-2 round, which closed Dec. 15.
- Real Estate
- Food & Drink
“There has never been a platform, at least in my experience, that has been able to do so much so quickly.” The science being done at SAB Biotherapeutics could be huge, not just for South Dakota but for human disease. We got a rare look at where it all will start.
The chief science officer for promising biotech startup SAB Biotherapeutics will update work at his company and give an overview of the bioscience landscape in South Dakota at an event Oct. 9 from the Zeal Center for Entrepreneurship.
SAB Biotherapeutics Inc., a Sioux Falls-based clinical stage biopharmaceutical development company, has received a $10 million investment from T. Denny Sanford.
Sioux Falls-based SAB Biotherapeutics used its anti-Ebola immunotherapy to provide 100 percent protection against a lethal dose of the disease in a recent animal study.
“There’s absolutely a rising tide in South Dakota.” We look at the road ahead for bioscience and the USD Discovery District following last week’s big announcement.
An emerging initiative called One Health is bringing together those who work in human medicine, veterinary medicine and environmental science, with big implications for the biotech industry in South Dakota.